FDA Approves Imlygic for Melanoma

Share this content:
FDA Approves Imlygic for Melanoma
FDA Approves Imlygic for Melanoma

WEDNESDAY, Oct. 28, 2015 (HealthDay News) -- Imlygic (talimogene laherparepvec) has been approved by the U.S. Food and Drug Administration to treat melanoma lesions of the skin and lymph nodes.

Imlygic, made from a genetically modified herpes virus, is approved to treat melanoma that cannot be completely surgically removed. It's injected directly into melanoma lesions, where it replicates inside cancer cells and causes the cells to rupture and die, the agency said. The drug is to be administered every two to three weeks for about six months, unless other treatment is needed or there are no additional lesions to treat, the FDA said.

Imlygic was evaluated in clinical studies involving 436 patients with metastatic melanoma that couldn't be removed by surgery. Some 16 percent of participants given the drug had lesions on the skin and lymph nodes decrease in size, compared to about 2 percent of participants given a placebo. However, the drug hasn't been proven to extend survival or to have an effect on melanoma that has advanced to inner organs such as the brain, bone, liver, or lungs, the agency said.

Imlygic's most common side effects include fatigue, chills, fever, nausea, flu-like symptoms, and injection-site pain. Since the product is derived from a modified live oncolytic herpes virus it is possible to acquire herpes virus infection from the drug and therefore shouldn't be given to people who are pregnant or have weakened immune systems.

The drug is produced by a subsidiary of Thousand Oaks, Calif.-based Amgen.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

CDC: Too Many Health Care Workers Not Getting Flu Vaccine

CDC: Too Many Health Care Workers Not Getting ...

Vaccination protects both workers and patients

Early Mobilization Improves Outcomes, LOS in Surgical ICUs

Early Mobilization Improves Outcomes, LOS in Surgical ICUs

Patients discharged sooner, become more functional when they leave the hospital

is free, fast, and customized just for you!

Already a member?

Sign In Now »